These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23138649)

  • 41. Malignant lymphomas: cell surface markers and advances in classification.
    Strauchen JA
    West J Med; 1981 Oct; 135(4):276-84. PubMed ID: 6979127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.
    Meeker T; Lowder J; Cleary ML; Stewart S; Warnke R; Sklar J; Levy R
    N Engl J Med; 1985 Jun; 312(26):1658-65. PubMed ID: 3923352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [AIDS-related primary central nervous system lymphoma].
    Hojo I
    No To Shinkei; 1997 Jan; 49(1):19-24. PubMed ID: 9027899
    [No Abstract]   [Full Text] [Related]  

  • 44. B cell receptor signaling in human systemic lupus erythematosus.
    Pugh-Bernard AE; Cambier JC
    Curr Opin Rheumatol; 2006 Sep; 18(5):451-5. PubMed ID: 16896281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
    Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
    [No Abstract]   [Full Text] [Related]  

  • 46. Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma.
    Nakamura T; Yamashita S; Fukumura K; Nakabayashi J; Tanaka K; Tamura K; Tateishi K; Kinoshita M; Fukushima S; Takami H; Fukuoka K; Yamazaki K; Matsushita Y; Ohno M; Miyakita Y; Shibui S; Kubo A; Shuto T; Kocialkowski S; Yamanaka S; Mukasa A; Sasayama T; Mishima K; Maehara T; Kawahara N; Nagane M; Narita Y; Mano H; Ushijima T; Ichimura K
    Acta Neuropathol; 2017 Feb; 133(2):321-324. PubMed ID: 28058506
    [No Abstract]   [Full Text] [Related]  

  • 47. Agammaglobulinemia: causative mutations and their implications for novel therapies.
    Berglöf A; Turunen JJ; Gissberg O; Bestas B; Blomberg KE; Smith CI
    Expert Rev Clin Immunol; 2013 Dec; 9(12):1205-21. PubMed ID: 24215410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Models of B-cell unresponsiveness.
    Scott DW; Alés-Martínez JE; Chace JH; LoCascio NJ; Silver L; Warner GL
    Cold Spring Harb Symp Quant Biol; 1989; 54 Pt 2():899-905. PubMed ID: 2701220
    [No Abstract]   [Full Text] [Related]  

  • 49. Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    Grommes C
    J Clin Oncol; 2023 Mar; 41(9):1649-1651. PubMed ID: 36669147
    [No Abstract]   [Full Text] [Related]  

  • 50. Rapid distinction of acute demyelinating disorders and central nervous system lymphoma by molecular analysis of cerebrospinal fluid cells.
    Wildemann B; Jansen O; Haas J; Vogt-Schaden ME; Storch-Hagenlocher B
    J Neurol; 2001 Feb; 248(2):127-30. PubMed ID: 11284130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma.
    Young RM; Turner BC; Refaeli Y
    Future Oncol; 2008 Oct; 4(5):591-4. PubMed ID: 18922114
    [No Abstract]   [Full Text] [Related]  

  • 52. Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets.
    Zeiser R; Negrin RS
    Blood; 2017 Jan; 129(1):1-2. PubMed ID: 27821507
    [No Abstract]   [Full Text] [Related]  

  • 53. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.
    Brat DJ; Cagle PT; Dillon DA; Hattab EM; McLendon RE; Miller MA; Buckner JC;
    Arch Pathol Lab Med; 2015 Sep; 139(9):1087-93. PubMed ID: 25642959
    [No Abstract]   [Full Text] [Related]  

  • 54. B-cell receptor signaling derailed in lymphomas.
    Klein U; Pasqualucci L
    Immunol Cell Biol; 2010; 88(4):346-7. PubMed ID: 20231849
    [No Abstract]   [Full Text] [Related]  

  • 55. Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.
    Yarmoska SK; Alawieh AM; Tomlinson S; Hoang KB
    Front Immunol; 2021; 12():689435. PubMed ID: 34671342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can B-cell signalling be understood?
    Sinclair NR
    Scand J Immunol; 1992 Feb; 35(2):125-30. PubMed ID: 1738815
    [No Abstract]   [Full Text] [Related]  

  • 57. Differential expression of neurofibromatosis 1 among discrete postnatal central nervous system progenitor populations.
    Sanai N
    World Neurosurg; 2011 Feb; 75(2):181-2. PubMed ID: 21492689
    [No Abstract]   [Full Text] [Related]  

  • 58. A B cell receptor variant confers evolutionary protection against pathogens.
    Nat Immunol; 2024 Oct; 25(10):1791-1792. PubMed ID: 39289559
    [No Abstract]   [Full Text] [Related]  

  • 59. Lymphoma and the nervous system.
    Ellison DW; Wilkins BS
    Curr Top Pathol; 2001; 95():239-65. PubMed ID: 11545056
    [No Abstract]   [Full Text] [Related]  

  • 60. PTPN1 is recurrently mutated in lymphoid cancers.
    Cancer Discov; 2014 Apr; 4(4):OF12. PubMed ID: 24706663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.